J-Pharma

Japan · Biotech

J-Pharma develops drugs that target SLC transporters, with programmes in cancer and autoimmune diseases.

Product

J-Pharma is a Japanese drug developer focused on SLC transporters, proteins involved in moving substances across cell membranes. Its research centres on LAT1, a transporter involved in amino-acid uptake and expressed at high levels in many cancer cells.

Its pipeline includes nanvuranlat, also known as JPH203, a small-molecule LAT1 inhibitor being studied for biliary tract cancer. The company is conducting the global Phase 3 Beacon-BTC trial and also works on treatments for autoimmune diseases.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
AMED GRiT grant≤¥1.5BJapan Agency for Medical Research and Development (AMED) — Participant
Sourcesj-pharma.com ↗j-pharma.com ↗